Market Cap 26.47B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 10.83
Forward PE 12.17
Profit Margin 16.87%
Debt to Equity Ratio 0.35
Volume 1,506,600
Avg Vol 1,826,898
Day's Range N/A - N/A
Shares Out 146.70M
Stochastic %K 14%
Beta 0.13
Analysts Sell
Price Target $178.26

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:10 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $175.84, showing strong momentum as it approaches its 60D high of $185.17. The RSI of 61.78 indicates bullish momentum, suggesting potential for further upside. Directional Bias: The current price is above the 30-day moving average (MA30) of 166.76 and the 50-day moving average (MA50) of 159.51, indicating a bullish trend. The RSI is not yet overbought, allowing room for growth. Trade Plan: - Suggested Entry: $176.00 - Stop Loss: $170.00 (3.4% below entry) - Take Profit Targets: - Target 1: $180.00 (2.3% gain) - Target 2: $185.00 (5.1% gain) - Target 3: $205.00 (16.6% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor the trade closely and adjust the stop loss to lock in profits as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
RunnerSignals
RunnerSignals Dec. 9 at 10:14 PM
$MDT $GOOG $AZN $BIIB $ACGL dips feel like discounts! Full insights for pro users only https://stocksrunner.com/news/2025-12-09-stocks-ready-to-bounce-back
0 · Reply
10_100_1000
10_100_1000 Dec. 9 at 9:07 PM
$BIIB LNAI SIGNIFICANT TUMOR REGRESSION Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy https://finviz.com/news/238325/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 9 at 6:58 PM
$IFRX New on X & bluesky reminder Inflarx isn’t a “me too” biotech - it’s cutting edge / small molecule oral & brand new technology. https://www.mdpi.com/1422-0067/26/23/11693 Courtesy: x giger1964 “With drug candidates targeting pathway-specific initiation (anti-C1s, anti-MASP2), amplification (FD and FB inh) and effector ft (C5aR1 inh) in late-stage devpt, we finally enter a new era in complement-modulating therapies" “..some inflammation-related tumors, sustained and excessively high levels of C5a can lead to fatigue or exhaustion of immune cells, reducing their ability to kill tumor cells. In cases where tumor cells are able to secrete C5a, it can upregulate the expression of chemokine MCP-1, and promote the metastasis of colon cancer cells to the liver through inflammatory infiltration mediated by MCP-1. In a mouse model of colon cancer liver metastasis, the expression level of C5a is also significantly increased.” $BIIB $AMGN $APLS all there - but Inflarx only pure play.
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Dec. 9 at 4:53 PM
Would not be surprised to see $RLYB get bought out in tandem with their C5 data this month. Given they are essentially a shell, have laid off 40% of their staff and the $BIIB C5 deal in October it makes sense to give their legacy VCs an exit (many with averages > $10)
2 · Reply
Chartist0_0
Chartist0_0 Dec. 9 at 2:33 PM
$BIIB within two weeks, I see this over 200$.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 9 at 10:14 AM
Enter: $BIIB Calls Strike Price: $185 Expiry Date: JAN 02 2026 Buy in Price: $3.70 - $4.75 Sell Price: $7.74 Profit : +63% (Turn every $1 into $1.63) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:58 PM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently experiencing strong momentum, closing at $181.37. The RSI at 79.27 indicates overbought conditions, suggesting a potential pullback. However, the stock remains above its MA30 (165.95) and MA50 (158.78), indicating a bullish trend. Directional Bias: Despite the high RSI, the proximity to the 60D High of 185.17 suggests potential for further upside. The recent price action indicates bullish sentiment, but caution is warranted due to overbought signals. Trade Plan: - Suggested Entry: $181.00 (slightly below the last close to capture potential pullback) - Stop Loss: $175.00 (below recent support levels) - Take Profit Targets: 1. $185.00 (2.25% gain) 2. $190.00 (4.80% gain) 3. $212.00 (17% gain) This plan allows for a structured approach to capitalize on potential upward movement while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
seeitmarket
seeitmarket Dec. 8 at 9:30 PM
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Dec. 8 at 8:52 PM
$ARWR so strong... tau tangles has been identified as a key cause for alzheimer. So excited about this prelim readout next year (late) ARO-MAPT for alzheimer. If this thing shows some progress this is co will be worth $25 - $30 billion and really it is just upside. no single company out there in this therapeutic class has demonstrated true efficacy. the latest approval leqembi from $BIIB is just as efficient as placebo (spoken in jest)
0 · Reply
Latest News on BIIB
AI Stocks Are Taking a Beating. What to Buy Instead.

Nov 21, 2025, 1:13 PM EST - 18 days ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY


Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 25 days ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS


Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 9:16 PM EDT - 5 weeks ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript


Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 2 months ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again


BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 2 months ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:10 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $175.84, showing strong momentum as it approaches its 60D high of $185.17. The RSI of 61.78 indicates bullish momentum, suggesting potential for further upside. Directional Bias: The current price is above the 30-day moving average (MA30) of 166.76 and the 50-day moving average (MA50) of 159.51, indicating a bullish trend. The RSI is not yet overbought, allowing room for growth. Trade Plan: - Suggested Entry: $176.00 - Stop Loss: $170.00 (3.4% below entry) - Take Profit Targets: - Target 1: $180.00 (2.3% gain) - Target 2: $185.00 (5.1% gain) - Target 3: $205.00 (16.6% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor the trade closely and adjust the stop loss to lock in profits as targets are reached. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
RunnerSignals
RunnerSignals Dec. 9 at 10:14 PM
$MDT $GOOG $AZN $BIIB $ACGL dips feel like discounts! Full insights for pro users only https://stocksrunner.com/news/2025-12-09-stocks-ready-to-bounce-back
0 · Reply
10_100_1000
10_100_1000 Dec. 9 at 9:07 PM
$BIIB LNAI SIGNIFICANT TUMOR REGRESSION Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy https://finviz.com/news/238325/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 9 at 6:58 PM
$IFRX New on X & bluesky reminder Inflarx isn’t a “me too” biotech - it’s cutting edge / small molecule oral & brand new technology. https://www.mdpi.com/1422-0067/26/23/11693 Courtesy: x giger1964 “With drug candidates targeting pathway-specific initiation (anti-C1s, anti-MASP2), amplification (FD and FB inh) and effector ft (C5aR1 inh) in late-stage devpt, we finally enter a new era in complement-modulating therapies" “..some inflammation-related tumors, sustained and excessively high levels of C5a can lead to fatigue or exhaustion of immune cells, reducing their ability to kill tumor cells. In cases where tumor cells are able to secrete C5a, it can upregulate the expression of chemokine MCP-1, and promote the metastasis of colon cancer cells to the liver through inflammatory infiltration mediated by MCP-1. In a mouse model of colon cancer liver metastasis, the expression level of C5a is also significantly increased.” $BIIB $AMGN $APLS all there - but Inflarx only pure play.
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Dec. 9 at 4:53 PM
Would not be surprised to see $RLYB get bought out in tandem with their C5 data this month. Given they are essentially a shell, have laid off 40% of their staff and the $BIIB C5 deal in October it makes sense to give their legacy VCs an exit (many with averages > $10)
2 · Reply
Chartist0_0
Chartist0_0 Dec. 9 at 2:33 PM
$BIIB within two weeks, I see this over 200$.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 9 at 10:14 AM
Enter: $BIIB Calls Strike Price: $185 Expiry Date: JAN 02 2026 Buy in Price: $3.70 - $4.75 Sell Price: $7.74 Profit : +63% (Turn every $1 into $1.63) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:58 PM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently experiencing strong momentum, closing at $181.37. The RSI at 79.27 indicates overbought conditions, suggesting a potential pullback. However, the stock remains above its MA30 (165.95) and MA50 (158.78), indicating a bullish trend. Directional Bias: Despite the high RSI, the proximity to the 60D High of 185.17 suggests potential for further upside. The recent price action indicates bullish sentiment, but caution is warranted due to overbought signals. Trade Plan: - Suggested Entry: $181.00 (slightly below the last close to capture potential pullback) - Stop Loss: $175.00 (below recent support levels) - Take Profit Targets: 1. $185.00 (2.25% gain) 2. $190.00 (4.80% gain) 3. $212.00 (17% gain) This plan allows for a structured approach to capitalize on potential upward movement while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
seeitmarket
seeitmarket Dec. 8 at 9:30 PM
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Dec. 8 at 8:52 PM
$ARWR so strong... tau tangles has been identified as a key cause for alzheimer. So excited about this prelim readout next year (late) ARO-MAPT for alzheimer. If this thing shows some progress this is co will be worth $25 - $30 billion and really it is just upside. no single company out there in this therapeutic class has demonstrated true efficacy. the latest approval leqembi from $BIIB is just as efficient as placebo (spoken in jest)
0 · Reply
andrewnyquist
andrewnyquist Dec. 8 at 7:36 PM
$BIIB Biogen is #33 on the MarketSurge Growth 250 List. Watching that breakout resistance line. #IBDpartner @MarketSurge @InvestorsBusinessDaily
0 · Reply
SparkyReturns
SparkyReturns Dec. 8 at 4:33 PM
$BIIB I'm surprised some of the large drug companies haven't noticed what ICU is doing.... Check out this investing idea. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again = 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in to ICU for those looking for an investing idea. Cheers! $SNY $TAK $RDY $TEVA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 7 at 6:28 PM
Enter: $BIIB Calls Strike Price: $185 Expiry Date: JAN 02 2026 Buy in Price: $4.50 - $4.75 Sell Price: $8.69 Profit : +83% (Turn every $1 into $1.83) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:59 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently trading at $181.98, near its 60D high of $185.17, indicating bullish momentum. However, the RSI at 75.78 suggests it may be overbought, warranting caution. Directional Bias: The price is above the 30-day MA of 163.86 and the 50-day MA of 156.99, which supports a bullish outlook. The high-low range indicates potential for upward movement, but the elevated RSI signals a possible pullback. Trade Plan: - Suggested Entry: $181.00 (anticipating a slight retracement) - Stop Loss: $175.00 (3% below entry) - Take Profit Targets: 1. $185.00 (2.2% gain) 2. $188.00 (3.3% gain) 3. $213.00 (17% gain) With these targets, the trade offers a favorable risk-reward ratio, especially with the potential for a significant upside at target 3. Monitor the price action closely to adjust the strategy if necessary. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 5 at 10:35 PM
Enter: $BIIB Calls Strike Price: $182 Expiry Date: DEC 26 2025 Buy in Price: $5.20 - $5.50 Sell Price: $11.39 Profit : +107% (Turn every $1 into $2.07) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TradingFUD
TradingFUD Dec. 5 at 5:20 PM
0 · Reply
Chartist0_0
Chartist0_0 Dec. 5 at 1:46 AM
$BIIB looking for a possible move to 210$ by YE. 280$ by end of March.
0 · Reply
TradingFUD
TradingFUD Dec. 4 at 3:02 PM
$LNTH Yesterday Eisai released data. Which supports the growth of Neuraceq. This is the data we needed to confirm Lantheus BULL THESIS! To be eligible for treatment with Leqembi, a patient must have a PET scan. Leqembi needs Neuraceq! The demand for Leqembi (lecanemab) has significantly increased the use of Neuraceq. $BIIB $XBI $LLY
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 4 at 2:47 PM
Enter: $BIIB Calls Strike Price: $182 Expiry Date: DEC 26 2025 Buy in Price: $5.20 - $5.50 Sell Price: $10.34 Profit : +88% (Turn every $1 into $1.88) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
GettnFibbywIT
GettnFibbywIT Dec. 4 at 2:02 PM
0 · Reply
Chartist0_0
Chartist0_0 Dec. 3 at 7:26 PM
$BIIB 280$ in 4 months
1 · Reply
GettnFibbywIT
GettnFibbywIT Dec. 3 at 3:00 PM
$BIIB $XLV Holding in early trading so far.....But its still early:
0 · Reply